# Study of MeRes100 in the Treatment of Patient With Coronary Artery Disease.

> **NCT03454724** · NA · UNKNOWN · sponsor: **Meril Life Sciences Pvt. Ltd.** · enrollment: 484 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DEVICE:** MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System
- **DEVICE:** Xience EES Everolimus Eluting Coronary Stent System

## Key facts

- **NCT ID:** NCT03454724
- **Lead sponsor:** Meril Life Sciences Pvt. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2020-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 484 (ESTIMATED)
- **Last updated:** 2019-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03454724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03454724, "Study of MeRes100 in the Treatment of Patient With Coronary Artery Disease.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03454724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*